Comparison of enrollees and decliners of Parkinson disease sham surgery trials

Movement Disorders

Volumn 27, Issue 4, 2012, Pages 506-511

  Kim, Scott Y H ^a,b   Wilson, Renee M ^c   Kim, H Myra ^b   Holloway, Robert G ^c,d   De Vries, Raymond G ^b   Frank, Samuel A ^e   Kieburtz, Karl ^c,d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Decision making; Gene transfer; Parkinson's disease; Sham surgery; Therapeutic misconception

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DECISION MAKING; DEMOGRAPHY; FEMALE; GENE TRANSFER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUROSURGERY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT ATTITUDE; PATIENT PARTICIPATION; PERCEPTION; PHASE 2 CLINICAL TRIAL (TOPIC); PIGMENT EPITHELIUM; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHAM PROCEDURE; SURGICAL RISK; THERAPEUTIC MISCONCEPTION;

AGED; ATTITUDE TO HEALTH; DECISION MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROSURGERY; PARKINSON DISEASE; RESEARCH SUBJECTS; RISK ASSESSMENT;

EID: 84862801182     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24940     Document Type: Article

References (12)

1. Jansen LA, Appelbaum PS, Klein WM, et al. Unrealistic optimism in early-phase oncology trials. IRB 2011; 33: 1-8.
2. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med 1999; 341: 992-996.
3. Kim SYH, Schrock L, Wilson RM, et al. An approach to evaluating the therapeutic misconception. IRB 2009; 31: 7-14.
4. Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2011; 10: 509-519.
5. Marks WJ, Jr., Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164-1172.
6. Kim SYH, Holloway RG, Frank S, et al. Volunteering for early phase gene transfer research in Parkinson disease. Neurology 2006; 66: 1010-1015.
7. Appelbaum PS, Lidz CW, Miller FG, Kimmelman J. Twenty-five years of therapeutic misconception. Hastings Cent Rep 2008; 38: 5-7.
8. Henderson GE, Easter MM, Zimmer C, et al. Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 2006; 62: 239-253.
9. Sulmasy DP, Astrow AB, He MK, et al. The culture of faith and hope. Cancer 2010; 116: 3702-3711.
10. Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 2003; 290: 1075-1082.
11. Fischhoff B, Bostrom A, Quadrel MJ. Risk perception and communication. Annu Rev Public Health 1993; 14: 183-203.
12. Hertwig R, Gigerenzer G. The 'conjunction fallacy' revisited: how intelligent inferences look like reasoning errors. J Behav Decis Mak 1999; 12: 275-305.